PMID- 17968528 OWN - NLM STAT- MEDLINE DCOM- 20081017 LR - 20220317 IS - 0012-186X (Print) IS - 0012-186X (Linking) VI - 51 IP - 1 DP - 2008 Jan TI - Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. PG - 198-207 AB - AIMS/HYPOTHESIS: Diabetic nephropathy is characterised by mesangial extracellular matrix accumulation. Monocyte chemoattractant protein-1 (MCP-1), a chemokine promoting monocyte infiltration, is upregulated in the diabetic glomerulus. We performed in vitro and in vivo studies to examine whether MCP-1 may have prosclerotic actions in the setting of diabetes, presumably via its receptor, chemokine (C-C motif) receptor 2 (CCR2), which has been described in mesangial cells. METHODS: Human mesangial cells were exposed to recombinant human (rh)-MCP-1 (100 ng/ml) for 12, 24 and 48 h and to rh-MCP-1 (10, 100 and 200 ng/ml) for 24 h. Fibronectin, collagen IV and transforming growth factor, beta 1 (TGF-beta1) protein levels were measured by ELISA and pericellular polymeric fibronectin levels by western blotting. The intracellular mechanisms were investigated using specific inhibitors for CCR2, nuclear factor kappa B (NF-kappaB), p38 mitogen-activated protein kinase and protein kinase C, and an anti-TGF-beta1 blocking antibody. In both non-diabetic and streptozotocin-induced diabetic mice that were deficient or not in MCP-1, glomerular fibronectin accumulation was examined by immunohistochemistry, while cortical Tgf-beta1 (also known as Tgfb1) and fibronectin mRNA and protein levels were examined by real-time PCR and western blotting. RESULTS: In mesangial cells, MCP-1 binding to CCR2 induced a 2.5-fold increase in fibronectin protein levels at 24 h followed by a rise in pericellular fibronectin, whereas no changes were seen in collagen IV production. MCP-1-induced fibronectin production was TGF-beta1- and NF-kappaB-dependent. In diabetic mice, loss of MCP-1 diminished glomerular fibronectin protein production and both renal cortical Tgf-beta1 and fibronectin mRNA and protein levels. CONCLUSIONS/INTERPRETATION: Our in vitro and in vivo findings indicate a role for the MCP-1/CCR2 system in fibronectin deposition in the diabetic glomerulus, providing a new therapeutic target for diabetic nephropathy. FAU - Giunti, S AU - Giunti S AD - Department of Internal Medicine, University of Turin, C.so AM Dogliotti, 14, 10126, Turin, Italy. sara_giunti@katamail.com FAU - Tesch, G H AU - Tesch GH FAU - Pinach, S AU - Pinach S FAU - Burt, D J AU - Burt DJ FAU - Cooper, M E AU - Cooper ME FAU - Cavallo-Perin, P AU - Cavallo-Perin P FAU - Camussi, G AU - Camussi G FAU - Gruden, G AU - Gruden G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20071030 PL - Germany TA - Diabetologia JT - Diabetologia JID - 0006777 RN - 0 (Chemokine CCL2) RN - 0 (Collagen Type IV) RN - 0 (Fibronectins) RN - 0 (NF-kappa B) RN - 0 (Transforming Growth Factor beta1) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) SB - IM MH - Animals MH - Chemokine CCL2/*genetics/*physiology MH - Collagen Type IV/metabolism MH - Diabetes Mellitus, Experimental/*metabolism MH - Diabetic Nephropathies MH - Enzyme-Linked Immunosorbent Assay MH - Fibronectins/metabolism MH - Humans MH - Mesangial Cells/*metabolism MH - Mice MH - Models, Biological MH - NF-kappa B/metabolism MH - Time Factors MH - Transforming Growth Factor beta1/metabolism MH - p38 Mitogen-Activated Protein Kinases/metabolism EDAT- 2007/10/31 09:00 MHDA- 2008/10/18 09:00 CRDT- 2007/10/31 09:00 PHST- 2007/06/22 00:00 [received] PHST- 2007/08/03 00:00 [accepted] PHST- 2007/10/31 09:00 [pubmed] PHST- 2008/10/18 09:00 [medline] PHST- 2007/10/31 09:00 [entrez] AID - 10.1007/s00125-007-0837-3 [doi] PST - ppublish SO - Diabetologia. 2008 Jan;51(1):198-207. doi: 10.1007/s00125-007-0837-3. Epub 2007 Oct 30.